BR112022014749A2 - Composto tricíclico fundido e uso medicinal do mesmo - Google Patents

Composto tricíclico fundido e uso medicinal do mesmo

Info

Publication number
BR112022014749A2
BR112022014749A2 BR112022014749A BR112022014749A BR112022014749A2 BR 112022014749 A2 BR112022014749 A2 BR 112022014749A2 BR 112022014749 A BR112022014749 A BR 112022014749A BR 112022014749 A BR112022014749 A BR 112022014749A BR 112022014749 A2 BR112022014749 A2 BR 112022014749A2
Authority
BR
Brazil
Prior art keywords
disease
diabetes
diabetic
retinopathy
heart failure
Prior art date
Application number
BR112022014749A
Other languages
English (en)
Portuguese (pt)
Inventor
Suzawa Koichi
Fujishima Yuki
Yamakawa Maki
Ueno Hiroshi
Manabe Tomoyuki
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BR112022014749A2 publication Critical patent/BR112022014749A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11002[Pyruvate dehydrogenase (acetyl-transferring)] kinase (2.7.11.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
BR112022014749A 2020-03-04 2021-03-03 Composto tricíclico fundido e uso medicinal do mesmo BR112022014749A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020036931 2020-03-04
JP2021001452 2021-01-07
PCT/JP2021/008055 WO2021177330A1 (ja) 2020-03-04 2021-03-03 縮合三環性化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
BR112022014749A2 true BR112022014749A2 (pt) 2022-10-11

Family

ID=77613417

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014749A BR112022014749A2 (pt) 2020-03-04 2021-03-03 Composto tricíclico fundido e uso medicinal do mesmo

Country Status (27)

Country Link
US (1) US20230025880A1 (https=)
EP (2) EP4663189A3 (https=)
JP (2) JP7739012B2 (https=)
KR (1) KR20220149688A (https=)
CN (1) CN115151543B (https=)
AU (1) AU2021230880A1 (https=)
BR (1) BR112022014749A2 (https=)
CA (1) CA3166747A1 (https=)
CL (1) CL2022002355A1 (https=)
CO (1) CO2022012548A2 (https=)
DK (1) DK4116301T3 (https=)
ES (1) ES3052010T3 (https=)
FI (1) FI4116301T3 (https=)
HR (1) HRP20251364T1 (https=)
IL (1) IL295836B2 (https=)
LT (1) LT4116301T (https=)
MX (1) MX2022010950A (https=)
PE (1) PE20221908A1 (https=)
PH (1) PH12022552259A1 (https=)
PL (1) PL4116301T3 (https=)
PT (1) PT4116301T (https=)
RS (1) RS67408B1 (https=)
SI (1) SI4116301T1 (https=)
SM (1) SMT202500464T1 (https=)
TW (1) TWI884224B (https=)
WO (1) WO2021177330A1 (https=)
ZA (1) ZA202209620B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114237A1 (es) * 2018-02-01 2020-08-05 Japan Tobacco Inc Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico
PL4116301T3 (pl) * 2020-03-04 2026-02-16 Japan Tobacco Inc. Skondensowany związek tricykliczny i jego zastosowanie medyczne
AU2022337617A1 (en) * 2021-09-01 2024-04-18 Japan Tobacco Inc. Nitrogen-containing tricyclic compound and pharmaceutical use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615647B1 (en) * 2003-04-11 2010-01-20 High Point Pharmaceuticals, LLC Pharmaceutical use of fused 1,2,4-triazoles
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
KR100808551B1 (ko) * 2006-12-01 2008-03-03 한국생명공학연구원 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
BR112015022077A2 (pt) * 2013-03-15 2017-07-18 Japan Tobacco Inc composto de pirazol-amida e usos medicinais do mesmo
EP3328857B1 (en) * 2015-07-31 2019-08-14 Merck Patent GmbH Bicyclic heterocyclic derivatives
AR114237A1 (es) * 2018-02-01 2020-08-05 Japan Tobacco Inc Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico
CN112638377A (zh) 2018-09-11 2021-04-09 日本烟草产业株式会社 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂
PL4116301T3 (pl) 2020-03-04 2026-02-16 Japan Tobacco Inc. Skondensowany związek tricykliczny i jego zastosowanie medyczne

Also Published As

Publication number Publication date
JP2025175000A (ja) 2025-11-28
WO2021177330A1 (ja) 2021-09-10
EP4663189A3 (en) 2026-02-25
CL2022002355A1 (es) 2023-03-03
ES3052010T3 (en) 2025-12-30
SMT202500464T1 (it) 2026-01-12
IL295836B2 (en) 2026-01-01
IL295836B1 (en) 2025-09-01
TWI884224B (zh) 2025-05-21
LT4116301T (lt) 2025-11-10
ZA202209620B (en) 2023-12-20
CN115151543B (zh) 2024-12-17
EP4663189A2 (en) 2025-12-17
CA3166747A1 (en) 2021-09-10
FI4116301T3 (fi) 2025-12-19
EP4116301A4 (en) 2024-04-03
CN115151543A (zh) 2022-10-04
EP4116301A1 (en) 2023-01-11
RS67408B1 (sr) 2025-12-31
PL4116301T3 (pl) 2026-02-16
JP2022007994A (ja) 2022-01-13
KR20220149688A (ko) 2022-11-08
PH12022552259A1 (en) 2023-11-20
US20230025880A1 (en) 2023-01-26
JP7739012B2 (ja) 2025-09-16
PE20221908A1 (es) 2022-12-23
EP4116301B1 (en) 2025-10-08
IL295836A (en) 2022-10-01
DK4116301T3 (da) 2025-10-20
HRP20251364T1 (hr) 2025-12-19
AU2021230880A1 (en) 2022-09-29
PT4116301T (pt) 2025-11-12
MX2022010950A (es) 2022-10-07
TW202146410A (zh) 2021-12-16
SI4116301T1 (sl) 2025-12-31
CO2022012548A2 (es) 2022-09-20

Similar Documents

Publication Publication Date Title
BR112022014749A2 (pt) Composto tricíclico fundido e uso medicinal do mesmo
PH12020500613A1 (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
TWI342776B (en) Carbostyril derivatives and mood stabilizers for treating mood disorders
JP2015510913A5 (https=)
Lien et al. Perioperative hypertension: defining at-risk patients and their management
US20200131121A1 (en) Usp30 inhibitors
RU2015144182A (ru) Пиразоламидное соединение и его применения в медицине
JP2019131544A5 (https=)
US20140058125A1 (en) Ortho-fluoro substituted compounds for the treatment of metabolic diseases
CO2024003629A2 (es) Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico
Brogden et al. Levodopa: A review of its pharmacological properties and therapeutic uses with particular reference to Parkinsonism
BR112015001056A2 (pt) composto, composição farmacêutica, métodos para o tratamento de distúrbios mediados pela aldosterona, para o tratamento de doença ou uma condição, para o tratamento da síndrome metabólica, para o tratamento de uma doença fisiológica ou patológica e para o tratamento da doença renal crônica, insuficiência renal ou nefropatia diabética
JP2022007994A5 (https=)
ZA202402435B (en) Nitrogen-containing tricyclic compound and pharmaceutical use thereof
JP2021520394A5 (https=)
JPWO2023032940A5 (https=)
Yahia et al. Ocular neovascularization in a patient with Fanconi anemia
Das Perioperative care of children with Eisenmenger syndrome undergoing non-cardiac surgery
Jenkins et al. Clinical Problems: Levodopa Therapy of Patients with Parkinsonism and Heart Disease
RU2024108335A (ru) Азотсодержащее трициклическое соединение и его фармацевтическое применение
WO1989011852A1 (fr) Agent de traitement de la pancreatite ou similaire
CA3208757A1 (en) Thiophene based compounds and use thereof as bckdk inhibitors
BR112022017942A2 (pt) Composição farmacêutica para prevenção ou tratamento de diabetes e doenças metabólicas associadas à mesma
CN117126148B (zh) 利伐沙班共晶及其制备方法
Mohammad Attenuation of cardiovascular response in medically controlled hypertensive patients during laryngoscopy and intubation undergoing abdominal surgeries under general anesthesia: a prospective study

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]